SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 13, 2010
(Exact name of registrant as specified in its charter)
|(State or other Jurisdiction of Incorporation)||(Commission File Number)||(IRS Employer Identification No.)|
|Science and Technology Park
at Johns Hopkins
855 N. Wolfe Street, Suite 619, Baltimore, MD
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s telephone number, including area code: (410) 369-0365
|(Former name or former address if changed since last report.)|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17 CFR
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
INFORMATION TO BE INCLUDED IN THE REPORT
Results of Operations and Financial Condition.
On December 13, 2010, Champions Biotechnology, Inc. (the “Company”) announced its results of operations for its second fiscal quarter ended October 31, 2010. A copy of the Company’s press release announcing such results dated December 13, 2010 is attached hereto as Exhibit 99.1. This Form 8-K and the attached exhibit are furnished to, but not filed with, the Securities and Exchange Commission (“SEC”) and shall not be deemed to be incorporated by reference into any of the Company’s filings with the SEC under the Securities Act of 1933.
Item 9.01. Financial Statements and Exhibits.
The following exhibits are filed herewith:
|Press Release dated December 13, 2010|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: December 13, 2010
By: /s/ Mark Schonau
Chief Financial Officer